From: Rivera, Donna (NIH/NCI) [F]
To: "Barbara M. Galligan"
Cc: Benjamin Chan
Subject: RE: SEER Data for NCI secondary malignancies
Date: Friday, June 24, 2016 7:24:12 AM
Attachments: Aml age adj data.csv

Hi Barbara,

I apologize for the delay in answering. I was out of the office. I am attaching a few options for types of analytic presentation for AML incidence. As for secondary malignancies, this is actually not easy to determine in SEER. There is a large amount of work around developing better algorithms for this. I have emailed the investigator working on secondary algorithms. Please let me know if these attached graphs (covering different years) are useful to you. There are several criteria I can apply to look at these in different ways or populations. Thank you!

Congrats on finishing up residency!!!!!!! ☺

Sincerely, Donna

Donna R. Rivera, PharmD., MSc.
Program Director
Clinical and Translational Epidemiology Branch
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850
Donna.Rivera@nih.gov
(240)276-6809

From: Barbara M. Galligan [mailto:bgalligan@ucdavis.edu]
Sent: Wednesday, June 22, 2016 2:10 PM
To: Benjamin Chan <chanb@ohsu.edu>; Rivera, Donna (NIH/NCI) [F] <donna.rivera@nih.gov>
Subject: Re: SEER Data for NCI secondary malignancies

Hi Donna,

Was wondering if you were able to make any progress finding somebody to help us get the SEER data for secondary malignancies? Thanks!
Barbara

From: Barbara M. Galligan

Sent: Friday, June 3, 2016 3:07:21 PM
To: Benjamin Chan; 'Rivera, Donna (NIH/NCI) [F]'
Subject: Re: SEER Data for NCI secondary malignancies

Hi,

Looks good, but one thing:

I think we do need the incidence of primary (de novo) and secondary AMLs (secondary to other cancers). We are trying to see if the incidence in our population is higher than de novo, so that would be helpful. Having the rate of secondary malignancies may help validate what we find.

Thanks!
Barbara

From: Benjamin Chan <chanb@ohsu.edu>
Sent: Friday, June 3, 2016 10:23:04 AM
To: 'Rivera, Donna (NIH/NCI) [F]'; Barbara M. Galligan
Subject: RE: SEER Data for NCI secondary malignancies

Hi Donna,

Barbara will probably chime in with different thoughts, but I'll take a stab at answering your questions. See below. Might want to hold off until Barbara responds.

From: Rivera, Donna (NIH/NCI) [F] [mailto:donna.rivera@nih.gov]
Sent: Friday, June 03, 2016 5:20 AM
To: Barbara M. Galligan; Benjamin Chan
Subject: RE: SEER Data for NCI secondary malignancies

Hi Barbara,

Happy to see if I can assist on this. If you can tell me the years, I want to confirm:

- AML Incidence (years??)

[BC] 1990-current

  - Do you need it by gender or age?

[BC] Just females age 40 y/o and older

- Difference in secondary versus primary AML? (incidence and/ or prevalence??)

[BC] Secondary AML, MDS, and AML+MDS combined. Don't need primary. Just need incidence.

If it is just this, I have the software on my computer and might be able to do it myself. Let me know! If you are going to ASCO, I might see you there☺

Thank you!

Sincerely,

Donna

Donna R. Rivera, PharmD., MSc.
Program Director
Clinical and Translational Epidemiology Branch
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850
Donna.Rivera@nih.gov
(240)276-6809

From: Barbara M. Galligan [mailto:bgalligan@ucdavis.edu]
Sent: Wednesday, June 01, 2016 1:24 PM
To: Rivera, Donna (NIH/NCI) [F]; Benjamin Chan
Subject: SEER Data for NCI secondary malignancies

Hi Donna,

Thank you for mentioning that you have a contact person who is familiar with SEER data for AML. We would like to know the standard incidence of AML. We are trying to divide out secondary vs primary AML occurrences. I think current incidence rate is sufficient. I'll let Ben comment if he needs something more specific for analysis. Ben - years that we are covering?

Thanks,
Barbara Galligan